secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274319
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q3 2025 net loss narrows to $7.0M; cash $48.7M; setrusumab data expected year-end
--------------------------------------------------------------------------------

- Net loss of $7.0M in Q3 2025 vs $15.0M in Q3 2024; operating loss of $10.0M.
- Cash and cash equivalents $48.7M as of Sep 30, 2025 (down from $69.8M Dec 31, 2024).
- R&D expenses rose to $4.3M (up $1.1M YoY) driven by setrusumab manufacturing and alvelestat Phase 3 prep.
- Phase 3 Orbit (p<0.039) and Cosmic (p<0.05) data for setrusumab in OI expected around end of 2025.
- Partnering discussions for alvelestat ongoing; vantictumab license to āshibio with retained EU rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/0001193125-25-274319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/mreo-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer